Cerca
Clinical factors associated with discontinuation of ts/ bDMARDs in rheumatic patients from the BIOBADASER III registry
(2021-05-27)
Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence ...
Guidance on brolucizumab management recommendations
(2022-07-23)